IZALONTAMAB BRENGITECAN
UNII UC2FX6YY3P

Substance Identification & Data

This profile provides standardized clinical and technical data for Izalontamab Brengitecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) UC2FX6YY3P.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2760528-47-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

UC2FX6YY3P

CAS Registry Number

2760528-47-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

IZALONTAMAB BRENGITECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C203048

National Cancer Institute reference terminology for clinical and research data.

INN ID

12678

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

MN-275

Identifier assigned by the United States Adopted Names Council.

Substance Type

Izalontamab Brengitecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Izalontamab Brengitecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Izalontamab Brengitecan

Common Names & Synonyms

BL B01D1 [WHO-DD]

Fused G1-scFv heavy-lambda heavy chain chimeric and Homo sapiens (1-702) [gamma1 heavy chain anti-EGFR chimeric (1-448) [VH (Mus musculus IGHV2-2*03 (93.8%) -(IGHD) -IGHJ3*01 (92.9%) A128>S (119), CDR-IMGT [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo sapiens IGHG1*08p (100%), G1m3,1 (CH1 I103 (201), R120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)] -10-mer bis(tetraglycyl-seryl) linker (449-458) -scFv heavy-lambda anti-ERBB3 Homo sapiens (459-702) [VH (Homo sapiens IGHV3-7*01 (91.8%) -(IGHD) -IGHJ2*01 (100%), CDR-IMGT [8.8.11] (484-491.509-516.555-565)) (459-576) -15-mer tris(tetraglycyl-seryl) linker (577-591) -V-LAMBDA (Homo sapiens IGLV2-14*03 (93.9%) -IGLJ2*01 (83.3%) L124>V (699), CDR-IMGT [9.3.11] (617-625.643-645.682-692)) (592-702)]], (222-214')-disulfide with kappa light chain anti-EGFR chimeric (1'-214') [V-KAPPA (Mus musculus IGKV5-48*01 (95.8%) -IGKJ5*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa; substituted at the sulfur atoms of the L -cysteinyl residues 214', 214''', 222, 222'', 228, 228'', 231, 231'' with (3RS)-1-[(4S,13S,21S)-13-benzyl-1-carboxy-22-{[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]amino}-21-methyl-5,8,11,14,17,22-hexaoxo-20-oxa-2,6,9,12,15,18-hexaazadocosan-4-yl]-2,5-dioxopyrrolidin-3-yl (brengitecan) groups

IZALONTAMAB BRENGITECAN [USAN]

Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 γ1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 κ-chain, dimer, 214′′,214′′′,222,222′,228,228′,231,231′-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-β-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide

Immunoglobulin G1-scFv_L-kappa dimer, anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)] and anti-[Homo sapiens ERBB3 (receptor tyrosine protein kinase erbB-3, HER3)], chimeric and Homo sapiens monoclonal antibody, tetravalent, bispecific, conjugated to a camptothecin derivative

izalontamab brengitecan [INN]